Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Pemvidutide cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established Pemvidutide cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Phase 1 MASLD trial: 12 weeks; extension: a further 12 weeks at the same dose (24 weeks in total) 1,2.
  2. IMPACT is a 48-week trial with dual primary endpoints at 24 weeks 3. PERFORMA lists histological endpoints at week 52 and a clinical-outcomes endpoint through approximately month 60 6.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Pemvidutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Pemvidutide cycle length?
No. Human studies administered Pemvidutide for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Pemvidutide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Pemvidutide dosing reference Full research page

References

  1. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study J Hepatol. 2025
  2. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial JHEP Rep. 2025
  3. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Lancet. 2025
  4. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis Sci Rep. 2022
  5. Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM, NCT05295875), registry record ClinicalTrials.gov. 2022
  6. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA, NCT07795164), registry record ClinicalTrials.gov. 2026
  7. RECLAIM: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (NCT06987513), registry record ClinicalTrials.gov. 2025
  8. RESTORE: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (NCT07009860), registry record ClinicalTrials.gov. 2025
  9. Drugs@FDA application data queried through openFDA for pemvidutide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  11. PubChem compound name search for pemvidutide (no compound record returned on 22 October 2026) PubChem. 2026
  12. IMPACT trial registration record (NCT05989711) ClinicalTrials.gov. 2023